milatuzumab-doxorubicin antibody-drug conjugate (hLL1-DOX) / Gilead - LARVOL DELTA

Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release. (PubMed, Eur J Med Chem) - "These prodrugs include albumin-binding prodrugs (Aldoxorubicin and DK049), polymeric micelle (NC-6300), polymer conjugates (ProLindac™), and an immunoconjugate (IMMU-110). The article encompasses a broad spectrum of studies focused on the development of acid-sensitive prodrugs for anticancer, antibacterial, and anti-inflammatory agents. Finally, the challenges associated with the acid-sensitive prodrug strategy are discussed, along with future directions."

Journal • Review • Infectious Disease • Oncology

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma (clinicaltrials.gov) - P1/2; N=17; Terminated; Sponsor: Immunomedics, Inc.; Completed ➔ Terminated; Study was terminated due to lack of efficacy

Clinical • Trial termination

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (clinicaltrials.gov) - P1/2; N=13; Terminated; Sponsor: Immunomedics, Inc.; N=30 ➔ 13

Enrollment change